E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
Wandercraft’s Eve exoskeleton enables wheelchair users to regain upright mobility and perform daily activities hands-free using self-balancing technology.
imphoenix82
US FDA has approved Lupin’s Sodium Zirconium Cyclosilicate for Oral Suspension as a bioequivalent to AstraZeneca’s Lokelma for the treatment of high levels of potassium in the blood, or hyperkalemia, in adults.
imphoenix82
Tudriqev is approved for use in combination with nivolumab to treat adults with unresectable advanced cutaneous melanoma after progression on an anti-PD-1-based regimen.
imphoenix82
If approved, BOTOX Cosmetic would become the only neurotoxin with five aesthetic indications and the first and only approved for masseter muscle prominence in the US.
imphoenix82
Lilly is currently evaluating olomorasib in the Phase 1/2 LOXO-RAS-20001 trial involving patients with KRAS G12C-mutant non-small cell lung cancer (NSCLC) and other advanced solid tumours.
imphoenix82
Chicago-based biopharmaceutical company Meitheal holds exclusive US commercialization rights for Garzulys through its exclusive license agreement with Emerge, the BLA holder.
imphoenix82
Teleflex has received Biologics License Application (BLA) approval for EZPLAZ Freeze Dried Plasma (FDP) from the USFDA.
imphoenix82
ELISIO-HX dialyzer, featuring NIPRO’s proprietary membrane technology, enhances middle molecule removal while remaining fully compatible with routine hemodialysis practice.
imphoenix82
Johnson & Johnson plans a phased commercial rollout of the OTTAVA system with select customers in the United States while working in parallel to advance into additional indications.
imphoenix82
Roche’s new PCR test simultaneously detects organisms associated with Bacterial vaginosis (BV) and Candida vaginitis (CV) from a single vaginal swab sample.
imphoenix82HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
